Danuglipron is a small-molecule GLP-1 receptor agonist that was under development as an oral pharmaceutical compound. It has been investigated for its effects on weight reduction and glycemic control, with nausea, diarrhea, and vomiting reported as common adverse events.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 2230198-02-2
3-Methylclobazam
pharmaceutical raw material
Clobazam impurity A CRS
pharmaceutical raw material
Clobazam
pharmaceutical raw material
Norclobazam
pharmaceutical raw material
2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]-2-pyridinyl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid
HYBAKUMPISVZQP-DEOSSOPVSA-N
C1CO[C@@H]1CN2C3=C(C=CC(=C3)C(=O)O)N=C2CN4CCC(CC4)C5=NC(=CC=C5)OCC6=C(C=C(C=C6)C#N)F